Johnson & Johnson COVID-19 vaccine update

The Food and Drug Administration (FDA) and Centers for Disease Control (CDC) have recommended a pause in the use of the Johnson & Johnson COVID-19 vaccine. According to the CDC, as of April 12, nearly 7 million doses of the Johnson & Johnson vaccine have been administered in the U.S. The agencies are reviewing data involving six reported U.S. cases of a rare type of blood clot in individuals after receiving the Johnson & Johnson vaccine.

COVID-19 vaccine safety is a top priority; the CDC has asked health care providers to report adverse events to the Vaccine Adverse Event Reporting System.

The AMA is closely monitoring developments and will provide additional information and resources once available.

CDC guidance

April 23, 2021

- AMA statement on ACIP reaffirming use of J&J vaccine in U.S. for persons 18 years of age and older

April 13, 2021

- CDC publishes action steps for clinicians: Cases of Cerebral Venous Sinus Thrombosis with Thrombocytopenia after Receipt of the Johnson & Johnson COVID-19 Vaccine
- CDC and FDA release a joint statement on reviewing data regarding the Johnson & Johnson COVID-19 vaccine.

Peter Marks, MD, PhD, on the Johnson & Johnson COVID-19 vaccine pause

April 13, 2021

In the latest "COVID-19: What Physicians Need to Know," webinar, Peter Marks, MD, PhD, Director
of the Center for Biologics Evaluation and Research at FDA, joins AMA President Susan R. Bailey to discuss the most up-to-date COVID-19 vaccine information, including the recent paused distribution of the Johnson & Johnson vaccine.

View the transcript.

AMA COVID-19 video updates discusses the Johnson & Johnson vaccine

April 16, 2021

Susan Bailey, MD, AMA president, recaps her discussion with Peter Marks, MD, PhD, director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, which covered the most up-to-date information on the rollout of the Janssen Pharmaceuticals vaccine and the other FDA-approved vaccines for COVID-19.

View the transcript and find more videos in this series.

April 15, 2021

Dr. Sandra Fryhofer—the AMA liaison to the CDC’s Advisory Committee on Immunization Practices and the AMA’s representative on the COVID-19 vaccine work group—provides a quick and comprehensive look at the emerging details regarding the J&J/ Janssen COVID-19 vaccine, and what physicians need to know about the vaccine pause.

View the transcript and find more videos in this series.

AMA news

- What doctors wish patients knew about the Johnson & Johnson vaccine
- J&J vaccine and brain blood clots: What physicians should know


Copyright 1995 - 2021 American Medical Association. All rights reserved.